About UNI-BIO GROUP Company

Liankang Biotechnology Group Limited (the “Company”) is a company listed on the main board of the Hong Kong Stock Exchange Limited (stock code: 0690). The core business of the Company and its subsidiaries (collectively referred to as “Liankang” or “Group”) is the research, development, manufacture and sale of innovative biological products that can treat human diseases. Liankang is headquartered in Hong Kong, while its main operations are located in mainland China. The Group strongly focuses on research and development (“R&D”) and has set up a high-quality professional team in Guangdong Province. The Group also has two GMP (“Good Manufacturing Practice”) certified production plants in Beijing and Shenzhen, which are responsible for the production of our sales products — voriconazole and epidermal growth factors. Currently, the Group has a new prescription drug, insulin-promoting hormone (“GLP-1”), has entered clinical testing, and a newly prescribed drug, human parathyroid hormone (1-34) (“UNI-PTH”), has obtained a drug registration certificate. Among them, GLP-1 is mainly aimed at patients with type 2 diabetes, especially those who are overweight. Uni-PTH is a course of treatment for postmenopausal women with osteoporosis (“NMPA”) marketing application approved by China National Drug Administration (“NMPA”) on January 16, 2024, with the approval number “Sinopharm Standard S20240004”). The Group's corporate philosophy is to improve our health by bringing high quality science and treatment to patients. To this end, the Group wholeheartedly serves patients through cooperation, thus ultimately becoming the “best partner” in China, bringing economic and important treatment plans to China.